Filing Analysis
Bicycle Therapeutics plc announced the resignation of Charles Swanton from the Board of Directors, effective August 18, 2026. The resignation was for personal reasons and not due to any disagreement with the company's operations or policies.
📋 Key Facts
- Charles Swanton resigned as a Class II director of the Board of Directors on August 18, 2026.
- Resignation includes his roles as a member of the Board's committees and the Clinical Advisory Board.
- The departure is effective immediately.
- The company explicitly states the resignation was for personal reasons and not due to disagreements regarding operations, policies, or practices.
Bicycle Therapeutics plc filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Report date: October 30, 2025
- Reporting period: Fiscal quarter ended September 30, 2025
- The company issued a press release (Exhibit 99.1) containing financial results and business highlights.
- The filing is made pursuant to Item 2.02 regarding Results of Operations and Financial Condition.
Bicycle Therapeutics plc announced an expansion of its Board of Directors, increasing the board size from eight to ten members. The company appointed two new independent directors: Dr. Roger Dansey and Hervé Hoppenot.
📋 Key Facts
- Board size increased from 8 to 10 directors effective September 8, 2025.
- Dr. Roger Dansey appointed as Class III director; term expires at the 2028 AGM.
- Hervé Hoppenot appointed as Class I director; term expires at the 2026 AGM.
- Dr. Dansey will serve on the Scientific Committee and Nominating and Corporate Governance Committee.
- Mr. Hoppenot will serve on the Audit Committee and Compensation Committee.
- Both appointees are deemed 'independent' by Nasdaq standards.
Bicycle Therapeutics plc announced its quarterly financial results for the period ending June 30, 2025, and appointed Dr. Charles Swanton to the Board of Directors and Scientific Committee.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Company released Q2 2025 financial results on August 8, 2025 (Exhibit 99.1).
- Dr. Charles Swanton appointed to the Board and Scientific Committee effective August 12, 2025.
- Dr. Swanton is classified as a non-independent director due to his prior service as Chair of the Clinical Advisory Board.
- Compensation for Dr. Swanton includes $50,000 annual cash for board service and $10,000 for scientific committee service.
- Equity compensation includes an option for 25,000 ordinary shares and 12,500 restricted share units (RSUs) vesting over three years.
Bicycle Therapeutics plc held its Annual General Meeting (AGM) on June 17, 2025. All proposed resolutions, including director re-elections and auditor ratifications, were successfully passed by shareholders.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- The AGM was held on June 17, 2025.
- A total of 49,135,059 ordinary shares (approx. 98.63% of issued and outstanding) were represented in person or by proxy.
- Proposal 1: Re-election of Alessandro Riva passed with 40,034,345 votes 'For'.
- Proposal 2: Re-election of Stephen Sands passed with 47,652,747 votes 'For'.
- Proposal 4 & 5: Ratification of PricewaterhouseCoopers LLP as both U.S. independent registered public accounting firm and U.K. statutory auditors.
- Proposal 9: Amendment to the Amended and Restated 2020 Equity Incentive Plan was approved with 38,137,068 votes 'For'.
Bicycle Therapeutics plc filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Report date: May 1, 2025
- Reporting period: Fiscal quarter ended March 31, 2025
- The company issued a press release (Exhibit 99.1) containing financial results and business highlights.
- The filing is made pursuant to Item 2.02 regarding Results of Operations and Financial Condition.
Bicycle Therapeutics plc issued an 8-K to furnish a press release regarding new human radiopharmaceutical imaging data for MT1-MMP presented at the AACR Annual Meeting 2025.
📋 Key Facts
- Filing date: April 29, 2025
- Event: Presentation of additional human radiopharmaceutical imaging data for MT1-MMP
- Context: American Association for Cancer Research (AACR) Annual Meeting 2025
- The information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Bicycle Therapeutics announced significant leadership changes, including the appointment of Dr. Alessandro Riva to the Board and Scientific Committee, alongside the resignation of Chief Development Officer Santiago Arroyo. Additionally, two directors (Pierre Legault and Richard Kender) will not stand for re-election at the upcoming 2025 Annual Meeting.
🚩 Red Flags
- Resignation of the Chief Development Officer (CDO) can be a signal of internal friction or strategic shifts in clinical pipeline management, though mitigated here by a consulting agreement.
- Multiple departures/non-renewals of Board members (Legault and Kender) occurring simultaneously with an officer departure.
📋 Key Facts
- Dr. Alessandro Riva appointed to the Board and Scientific Committee effective March 25, 2025; he is expected to join the Audit Committee after the June 17, 2025 Annual Meeting.
- Chief Development Officer Santiago Arroyo resigned effective March 24, 2025, but will remain as a consultant for a two-year term (with potential one-year extension) at $12,000 annually.
- Directors Pierre Legault and Richard Kender will retire from the Board following the June 17, 2025 Annual Meeting; no disagreements were reported regarding their departures.
- Dr. Riva's compensation includes $50,000 annual cash for board service, $10,000 for Scientific Committee, and a potential $15,000 for Audit Committee, plus 25,000 share options and 12,500 RSUs.
- The company's Annual General Meeting is scheduled for June 17, 2025.
Bicycle Therapeutics plc has announced the date for its 2025 Annual General Meeting (AGM) as June 17, 2025. The filing serves to establish deadlines for shareholder proposals and director nominations in accordance with SEC and U.K. Companies Act requirements.
📋 Key Facts
- The 2025 Annual General Meeting is scheduled for June 17, 2025.
- Shareholder proposals for inclusion in proxy materials must be submitted by March 31, 2025.
- Proposals not intended for inclusion in proxy materials or director nominations under Rule 14a-19 must be submitted by April 18, 2025.
- Under the U.K. Companies Act 2006, shareholders meeting specific thresholds (5% voting rights or 100+ shareholders) may require a resolution notice by May 5, 2025.
Bicycle Therapeutics plc announced its financial results for the fiscal quarter and full year ended December 31, 2024. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Reported date: February 25, 2025
- Covers financial results for the fiscal quarter and year ended December 31, 2024
- Includes business highlights alongside financial performance
- The information is furnished under Item 2.02 of Form 8-K
Bicycle Therapeutics released updated topline Phase 1 data for zelenectide pevedotin in combination with pembrolizumab and outlined its strategic priorities for 2025. The clinical data showed a 65% overall response rate (ORR) in first-line cisplatin-ineligible patients.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Updated Phase 1 Duravelo-1 trial results for zelenectide pevedotin + pembrolizumab as of January 3, 2025 data cut-off.
- 65% overall response rate (ORR) observed among all efficacy-evaluable patients (13/20).
- 50% ORR among patients with confirmed responses (10/20).
- Median duration of response (mDOR) is currently immature; 12 patients remain on treatment.
- Safety profile reported as broadly consistent with previous monotherapy and combination cohorts, with no Grade 4 or 5 treatment-related adverse events (TRAEs) of clinical interest.
Bicycle Therapeutics plc issued an 8-K to announce data updates regarding its zelenectide pevedotin program and a development strategy focused on NECTIN4 gene amplification. The company also hosted a conference call/webcast to review these clinical updates.
📋 Key Facts
- Announced data updates for the zelenectide pevedotin program on December 12, 2024.
- Disclosed a development strategy leveraging NECTIN4 gene amplification.
- Conducted a conference call and webcast on December 13, 2024, to review clinical data.
Bicycle Therapeutics plc filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024. The filing serves as a formal notification of the release of quarterly earnings and business updates.
📋 Key Facts
- Report date: October 31, 2024
- Reporting period: Fiscal quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and business highlights.
- The company is listed on the Nasdaq Stock Market LLC under ticker BCYC.
Bicycle Therapeutics plc issued an 8-K to announce the presentation of first human imaging data for its MT1-MMP target at the EANM 2024 Congress. The filing also outlines the company's strategic direction toward developing radiopharmaceuticals.
📋 Key Facts
- Announced presentation of first human imaging data validating MT1-MMP as a novel cancer treatment target.
- Presented at the European Association of Nuclear Medicine (EANM) 2024 Congress in Hamburg, Germany.
- Outlined company strategy for radiopharmaceutical development.
Bicycle Therapeutics plc issued an 8-K to announce updated clinical trial results for three of its drug candidates: zelenectide pevedotin (BT8009), BT5528, and BT7480. The filing serves as a vehicle to incorporate the company's press release regarding these clinical developments into the public record.
📋 Key Facts
- Announced updated clinical results for zelenectide pevedotin (formerly BT8009) in mUC (metastatic urothelial carcinoma).
- Announced updated clinical results for BT5528 in advanced solid tumors.
- Announced updated clinical results for BT7480 in advanced solid tumors.
- The announcement was made via press release on September 14, 2024.
Bicycle Therapeutics plc filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024. The filing serves as a formal notification that a press release containing business highlights and quarterly financials has been issued.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2024.
- Filing date: August 6, 2024.
- The filing includes the announcement of financial results and other business highlights via Exhibit 99.1.
Bicycle Therapeutics plc has voluntarily terminated and fully repaid its $30 million term loan with Hercules Capital, Inc. The company utilized cash on hand to settle the debt, including all interest and prepayment charges.
🚩 Red Flags
- Prepayment/end-of-term charges totaling $1.8 million incurred to exit the debt early.
📋 Key Facts
- Repaid $31.9 million in total aggregate payment to terminate the Loan Agreement dated September 30, 2020.
- The repayment included principal, accrued/unpaid interest, a $1.5 million end-of-term charge, and a $0.3 million prepayment charge.
- The outstanding principal amount was $30.0 million of an original $75.0 million facility.
- The loan was secured by a senior security interest in substantially all personal property and assets (excluding intellectual property).
- All security interests granted to Hercules Capital, Inc. have been terminated and released.
Bicycle Therapeutics plc filed a prospectus supplement to its existing S-3ASR registration statement. This filing relates to the resale of up to 37,656,764 ordinary shares by certain selling securityholders.
🚩 Red Flags
- Significant volume of shares being made available for resale (37.6M shares), which can create downward pressure on stock price due to increased supply.
📋 Key Facts
- Filed a prospectus supplement to effective registration statement on Form S-3ASR (File No. 333-272248).
- The filing concerns the resale of up to 37,656,764 ordinary shares.
- Each ordinary share is represented by one American Depositary Share (ADS).
- Includes a legal opinion from Cooley (UK) LLP regarding the validity of the shares.
Bicycle Therapeutics entered into a securities purchase agreement for a private placement of 25,933,706 American Depositary Shares (ADSs) at $21.42 per share. The transaction is expected to raise approximately $555 million in gross proceeds, significantly extending the company's cash runway.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of ~25.9 million new shares.
📋 Key Facts
- Entered into a securities purchase agreement on May 23, 2024.
- Total shares to be issued: 25,933,706 ADSs (or non-voting ordinary shares).
- Offering price: $21.42 per share.
- Estimated aggregate gross proceeds: ~$555 million.
- Expected closing date: May 28, 2024.
- Post-closing estimated cash and cash equivalents: ~$1.0 billion.
- Anticipated financial runway extension: into the second half of 2027.
Bicycle Therapeutics plc held its Annual General Meeting (AGM) on May 16, 2024. All proposed ordinary and special resolutions were successfully passed by shareholders.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- The AGM was held on May 16, 2024.
- Quorum represented approximately 98.19% of the issued and outstanding ordinary shares (37,398,107 shares).
- Shareholders re-elected directors Kevin Lee and Jose-Carlos Gutierrez-Ramos.
- PricewaterhouseCoopers LLP was ratified as both U.S. independent registered public accounting firm and U.K. statutory auditors for the year ending December 31, 2024.
- Shareholders approved the adoption of new articles of association (Proposal 11).
- The Board received authorization to allot shares/grant rights up to a maximum aggregate nominal amount of £1,000,000 (Proposal 9 and 10).
Bicycle Therapeutics plc filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024. The filing serves as a formal notice that a press release containing these results was issued on May 2, 2024.
📋 Key Facts
- Reporting period: Fiscal quarter ended March 31, 2024.
- Filing date: May 2, 2024.
- The filing incorporates a press release (Exhibit 99.1) by reference regarding financial results and business highlights.
Bicycle Therapeutics announced a leadership transition involving the resignation of Dr. Veronica Jordan from the Board and her appointment as a consultant, alongside the appointment of Dr. Felix J. Baker to the Board. Additionally, the company entered into an Affiliate Registration Rights Agreement with BBA Funds, a major shareholder holding over 10% of the company.
🚩 Red Flags
- Related-party transaction: The new director, Dr. Felix J. Baker, is associated with the BBA Funds, which hold >10% of the company's shares.
- Potential dilution/liquidity risk: The registration rights agreement allows a major shareholder (BBA Funds) to request underwritten offerings or block trades to liquidate their position.
📋 Key Facts
- Dr. Veronica Jordan resigned as Class I director, Chair of Compensation Committee, and Audit Committee member effective April 17, 2024.
- Dr. Jordan will continue to serve the company under a two-year consulting agreement with compensation of GBP 12,000 per year.
- Dr. Felix J. Baker was appointed to the Board as a Class I director, effective April 18, 2024.
- The BBA Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) hold more than 10% of the Company's outstanding shares.
- An Affiliate Registration Rights Agreement was executed with BBA Funds, granting them rights to request resale registration statements on Form S-3 or underwritten offerings.
Bicycle Therapeutics plc announced its financial results for the fiscal year and quarter ended December 31, 2023, and appointed Stephen Sands to its Board of Directors.
📋 Key Facts
- Company released Q4 and FY 2023 financial results via press release on February 20, 2024.
- Stephen Sands appointed to the Board as a Class III director, effective February 20, 2024.
- Mr. Sands designated as an 'independent' director under Nasdaq rules.
- Mr. Sands will serve on the Audit and Strategic Committees.
- Director compensation includes $50,000 annual cash for board service, $10,500 for Audit Committee, and $33,000 for Strategic Committee.
- Equity compensation includes options for 24,000 ordinary shares and RSUs for 12,000 ordinary shares, vesting over three years.